CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 500 filers reported holding CRISPR THERAPEUTICS AG in Q2 2021. The put-call ratio across all filers is 1.18 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $590 | -85.2% | 13 | -80.6% | 0.00% | – |
| Q2 2022 | $4,000 | -99.3% | 67 | -98.1% | 0.00% | -100.0% |
| Q2 2021 | $570,000 | +2180.0% | 3,521 | +2008.4% | 0.04% | +1400.0% |
| Q4 2020 | $25,000 | -51.9% | 167 | -76.8% | 0.00% | -57.1% |
| Q2 2020 | $52,000 | +550.0% | 721 | +256.9% | 0.01% | +40.0% |
| Q1 2020 | $8,000 | -95.5% | 202 | -93.0% | 0.01% | -70.6% |
| Q4 2019 | $176,000 | +175.0% | 2,900 | +104.7% | 0.02% | +183.3% |
| Q1 2018 | $64,000 | – | 1,417 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $31,294,000 | 31.24% |
| NEA Management Company, LLC | 1,590,002 | $365,593,000 | 10.56% |
| Ariose Capital Management Ltd | 37,900 | $2,379,000 | 9.30% |
| ARK Investment Management | 9,404,071 | $590,294,000 | 2.46% |
| NIA IMPACT ADVISORS, LLC | 80,082 | $5,027,000 | 2.44% |
| Nikko Asset Management Americas, Inc. | 4,619,747 | $291,044,000 | 2.14% |
| PLUSTICK MANAGEMENT LLC | 50,000 | $3,139,000 | 1.98% |
| Integral Health Asset Management, LLC | 120,000 | $7,532,000 | 1.96% |
| Valiant Capital Management, L.P. | 240,683 | $15,108,000 | 1.73% |
| Deuterium Capital Management, LLC | 18,000 | $1,130,000 | 1.45% |